Carag Applies Bioabsorbable Material Technology To Transseptal Occluders
Executive Summary
The Swiss company is planning a US trial of CBSO, the first transcatheter septal occluder with a bioresorbable, metal-free frame.
You may also be interested in...
Abbott Sees Signs Of Post-Pandemic Recovery In Q2
Abbott’s medical device sales were down about 20% year-over-year in the second quarter of 2020, but diagnostics sales were up 7%. Procedure trends at the end of the second quarter suggest that demand for devices will soon recover to pre-pandemic levels.
News We’re Watching: SALSA Reintroduced, FDA Approves Abbott Valve, Metallic Implant Study
A bill aimed at preventing laboratory reimbursement cuts has been reintroduced in the US Congress. Additionally, an Abbott valve landed FDA approval, On Target Labs reported trial results, and the FDA warned that dental palate expanders may pose health risks to adults.
Minute Insight: Xeltis Expects The US Trial Of 'Living' Vascular Graft To Start This Year
Xeltis hemodialysis access graft, made of its proprietary electrospun supramolecular polymer material, is advancing in clinical trials in Europe and will likely be ready for a US trial by the end of this year, according to the company.